North American Construction Group Ltd. Reschedules Fourth Quarter Results Conference Call and Webcast
The Company is rescheduling the release of its financial results and related conference call to allow it more time to complete the year-end reporting processes within its Heavy Equipment - Australia segment. The additional time is necessary due to first-year SOX reporting requirements, high activity levels at year-end and its implementation of a new ERP system, all within the segment which was previously a privately held entity.
The call can be accessed by dialing:
Toll free: 1-800-717-1738
Conference ID: 71653
A replay will be available through April 13, 2025, by dialing:
Toll Free: 1-888-660-6264
Conference ID: 71653
Playback Passcode: 71653
A slide deck for the webcast will be available for download the evening prior to the call and will be found on the company's website at www.nacg.ca/presentations/
A replay will be available until April 13, 2025, using the link provided.
About the Company
North American Construction Group Ltd. is a premier provider of heavy civil construction and mining services in Australia, Canada and the U.S. For over 70 years, NACG has provided services to the mining, resource and infrastructure construction markets.
For further information, please contact:
Jason Veenstra, CPA, CA
Chief Financial Officer
North American Construction Group Ltd.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
18 minutes ago
- Business Wire
Earnings Teleconference Moves to Earlier Time on July 29
--(BUSINESS WIRE)--As previously announced, UnitedHealth Group will release its second quarter 2025 financial results on Tuesday, July 29, 2025, before the market opens. The start time for the teleconference has moved to 8:00 a.m. ET, 45 minutes earlier than previously announced, to allow more time for discussion of results with analysts and investors. This call will be webcast on the Investor Relations page of the company's website ( The replay will be available through August 12 on the website. UnitedHealth Group (NYSE: UNH) is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone through two distinct and complementary businesses. Optum delivers care aided by technology and data, empowering people, partners and providers with the guidance and tools they need to achieve better health. UnitedHealthcare offers a full range of health benefits, enabling affordable coverage, simplifying the health care experience and delivering access to high-quality care. Visit UnitedHealth Group at and follow UnitedHealth Group on LinkedIn.
Business Wire
18 minutes ago
- Business Wire
SYNOVUS FINANCIAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Synovus Financial Corp.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed merger of Synovus Financial Corp. (NYSE: SNV) and Pinnacle Financial Partners (NasdaqGS: PNFP). Upon completion of the proposed transaction, Synovus shareholders will own approximately 48.5% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to Synovus shareholders. If you would like to discuss your legal rights regarding the proposed transaction, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit
Yahoo
34 minutes ago
- Yahoo
Why Elanco (ELAN) Stock Is Trading Up Today
What Happened? Shares of animal health company Elanco (NYSE:ELAN) jumped 3% in the pre-market session after the company received approval from the European Commission for its canine dermatitis treatment, Zenrelia. The treatment, Zenrelia, was approved as a once-daily oral medication to treat itching and atopic dermatitis in dogs. This decision by the European Commission represented a significant milestone for Elanco, allowing it to expand its presence in the European canine dermatology market. The company stated the product was expected to be available by the end of the third quarter of 2025. The news followed a recent analyst upgrade from UBS Group, which raised its price target on Elanco shares to $18.00 from $17.00, reiterating a 'buy' rating on the stock. After the initial pop the shares cooled down to $14.85, up 1.1% from previous close. Is now the time to buy Elanco? Access our full analysis report here, it's free. What Is The Market Telling Us Elanco's shares are quite volatile and have had 16 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The biggest move we wrote about over the last year was 3 months ago when the stock gained 21.2% on the news that the company reported decent first quarter 2025 results which beat analysts' EPS expectations and included constant currency revenue outperformance. Organic sales were up 4%, thanks to strong demand in cattle health and good traction from new pet meds like Credelio Quattro. Even though sales were flat, operating margins improved, a sign they're managing prices and costs pretty well. On the other hand, its full-year EBITDA guidance missed. Overall, we think this was a decent quarter with some key metrics above expectations. Elanco is up 23.2% since the beginning of the year, and at $14.85 per share, it is trading close to its 52-week high of $15.47 from August 2024. Investors who bought $1,000 worth of Elanco's shares 5 years ago would now be looking at an investment worth $696.95. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
